Yeonsun Hong Selected Research

Neoplasms (Cancer)

7/2023	Exosome-guided direct reprogramming of tumor-associated macrophages from protumorigenic to antitumorigenic to fight cancer.
1/2023	ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.
1/2023	PD-1Hi CAR-T cells provide superior protection against solid tumors.
11/2022	Advantage of extracellular vesicles in hindering the CD47 signal for cancer immunotherapy.
1/2022	Mechanically active integrins target lytic secretion at the immune synapse to facilitate cellular cytotoxicity.
1/2021	In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
1/2020	In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In Vivo.
1/2020	Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade.
1/2020	Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity.
1/2019	Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yeonsun Hong Research Topics

Disease

18	Neoplasms (Cancer) 07/2023 - 05/2015
3	Melanoma (Melanoma, Malignant) 01/2021 - 05/2015
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Thrombocytopenia (Thrombopenia) 11/2022
1	Anemia 11/2022
1	Uveal melanoma 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 11/2017
1	Stomatitis 04/2017
1	Lung Neoplasms (Lung Cancer) 05/2015

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 07/2023 - 01/2017
2	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2023
2	rho-Associated KinasesIBA 01/2021 - 01/2018
2	Ferritins (Ferritin)IBA 10/2018 - 12/2017
2	Peptides (Polypeptides)IBA 03/2018 - 12/2017
1	SpectrinIBA 01/2023
1	AntibodiesIBA 11/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2022
1	PerforinIBA 01/2022
1	Granzymes (Granzyme)IBA 01/2022
1	K-115IBA 01/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	mannosamine (D-mannosamine)IBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	Viral AntigensIBA 01/2020
1	AzidesIBA 01/2020
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2020
1	peracetylated N-azidoacetylmannosamineIBA 01/2020
1	monophosphoryl lipid AIBA 01/2020
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2019
1	Coloring Agents (Dyes)IBA 01/2019
1	LigandsIBA 03/2018
1	ErbB Receptors (EGF Receptor)IBA 12/2017
1	Inosine Diphosphate (IDP)IBA 12/2017
1	Intrinsically Disordered ProteinsIBA 12/2017
1	Poly (ADP-Ribose) Polymerase-1IBA 11/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 04/2017
1	GTP-Binding Proteins (G-Protein)IBA 04/2017
1	SAN7401IBA 05/2015
1	hydroquinone (Esoterica)FDA Link 05/2015
1	Antineoplastic Agents (Antineoplastics)IBA 05/2015
1	VemurafenibIBA 05/2015

Therapy/Procedure

8	Therapeutics 01/2023 - 01/2017
7	Immunotherapy 01/2023 - 01/2018
1	Ligation 11/2022
1	Photochemotherapy (Photodynamic Therapy) 01/2021